Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb (NYSE:BMY) on Thursday noticed a decline in its stock price. This after saying it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to ...

Trump’s “buyout” offer (aka the “agree with me or leave” special) has hit the CIA.

A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Government Initiatives and Expanding Access to Medication-Assisted Treatment (MAT) Drive Growth in Opioid Use Disorder (OUD) MarketAustin, United States, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opioid Use ...

The executive order could come as soon as next week, if the Trump administration goes ahead with plans, according to people ...

Senator Cory Booker and Representative Rosa DeLauro introduced a bill to provide FDA the authority to collect microbial ...

For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...